Evaluation of the Safety, Tolerability and PK Characteristics of GV1001 in Healthy Subjects

NCT06625710 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuro-Degenerative Disease

Interventions

DRUG: GV1001
DRUG: Placebo

Sponsor

GemVax & Kael